Celgene Pomalyst Sales Surpass Amgen's Kyprolis; EU Approval Key
2014-10-29 18:21:33.304 GMT
Sales of Celgene's Pomalyst for refractory multiple myeloma patients are almost double those of Amgen's Kyprolis, even with the latter's almost seven-month lead in FDA approval. Amgen will need to gain approval in Europe to successfully compete with Celgene. A survival miss in the Phase III Focus trial may place Amgen's competitive position at risk, given the trial was designed for EU approval. Survival is a more important factor for approval by the EMA than the FDA.